3B Pharmaceuticals Entered into an Amended and RestatedLicense Agreement with Novartis for FAP-Targeting Peptide Technology
Shots:
- 3BP to receive an initial fee of $40M and is eligible to receive an additional ~$425M in development, regulatory, and commercial milestones along with royalties on net sales
- 3BP retains certain rights to develop its FAP-targeting imaging technology for diagnostic purposes. Novartis gets an exclusive right globally to develop and commercialize therapeutic and imaging applications for 3BP's FAP-targeting peptide technology, incl. FAP-2286, the first peptide-targeted radioligand therapy (PT-RLT) targeting FAP currently being studied in the P-I trial (LuMIERE)
- In 2019, 3BP collaborated with Clovis Oncology on the development of a peptide-targeted radiotherapy and imaging agent targeting FAP
Ref: 3B Pharmaceuticals | Image: Novartis
Related News:- Clovis Oncology Signs a License Agreement with 3B Pharmaceuticals for FAP-Targeted Radiopharmaceutical Program
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
